NCT05982574Active, not recruiting
Tumor Microenvironment
Tumor Microenvironment in Lung Adenocarcinoma
Source: ClinicalTrials.gov · Last updated 8 May 2024
Brief summary (registry, in English)
Cancer immunotherapy has the great potential to achieve long-term survival in patients with a solid malignancy. However, the beneficial effect of cancer immunotherapy is seen in only a minority of patients. Mounting evidence suggests that immunosuppressive features in the tumor microenvironment prevent an effective antitumor defense. The aim of the investigators is to comprehensively analyze the cytokine profile and the tumor immune infiltrate in the tumor microenvironment and to investigate its prognostic significance in patients with radically resected lung adenocarcinoma.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 30 Jul 2023
- Start date
- Feb 2016
- Primary completion date
- Feb 2026
- Lead sponsor
- University Hospital Heidelberg
- Diseases
- Lung cancer
- NCT number
- NCT05982574
What you commit to
- Study type: Observational
- Planned participants: 300
- From Feb 2016 to the primary completion date, Feb 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Second cancer within 5 years
Who the study is looking for
- Lung adenocarcinoma
- Tumor stage IB and II
- With or without adjuvant therapy
- Complete surgical resection (R0)
- No distant metastasis at the time of surgery (M0)
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.